Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia

Steven Trifilio*, Zheng Zhou, Jayesh Mehta, Colleen Czerniak, Judy Pi, Deborah Greenberg, Molly Koslosky, Mihaela Pantiru, Jessica Altman

*Corresponding author for this work

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Daunorubicin has historically been considered the anthracycline of choice at many cancer centers for the treatment of acute myeloid leukemia (AML). Drug shortages have required the substitution of daunorubicin with idarubicin. Randomized studies have shown idarubicin (10-12mg/m2) to be comparable or superior to standard dose daunorubicin (45-60mg/m2) for achieving complete remission (CR). Whether these results can be extrapolated to dose-intense daunorubicin (90mg/m2), recently shown to improve CR rates when compared to standard daunorubicin doses remains uncertain. This observational study was conducted at Northwestern Memorial Hospital (NMH) to compare CR rates. The results suggest idarubicin is equivalent to daunorubicin, and for some subsets of patients, idarubicin may have superior CR rates.

Original languageEnglish (US)
Pages (from-to)868-871
Number of pages4
JournalLeukemia Research
Volume37
Issue number8
DOIs
StatePublished - Aug 2013

Keywords

  • Acute leukemia
  • Daunorubicin
  • Idarubicin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this